» Articles » PMID: 36257966

Reprogramming of Myeloid Cells and Their Progenitors in Patients with Non-medullary Thyroid Carcinoma

Abstract

Myeloid cells, crucial players in antitumoral defense, are affected by tumor-derived factors and treatment. The role of myeloid cells and their progenitors prior to tumor infiltration is poorly understood. Here we show single-cell transcriptomics and functional analyses of the myeloid cell lineage in patients with non-medullary thyroid carcinoma (TC) and multinodular goiter, before and after treatment with radioactive iodine compared to healthy controls. Integrative data analysis indicates that monocytes of TC patients have transcriptional upregulation of antigen presentation, reduced cytokine production capacity, and overproduction of reactive oxygen species. Interestingly, these cancer-related pathological changes are partially removed upon treatment. In bone marrow, TC patients tend to shift from myelopoiesis towards lymphopoiesis, reflected in transcriptional differences. Taken together, distinct transcriptional and functional changes in myeloid cells arise before their infiltration of the tumor and are already initiated in bone marrow, which suggests an active role in forming the tumor immune microenvironment.

Citing Articles

Thyroid Cancer-The Tumor Immune Microenvironment (TIME) over Time and Space.

Jaume J Cancers (Basel). 2025; 17(5).

PMID: 40075642 PMC: 11899416. DOI: 10.3390/cancers17050794.


Single-cell immune aging clocks reveal inter-individual heterogeneity during infection and vaccination.

Li W, Zhang Z, Kumar S, Botey-Bataller J, Zoodsma M, Ehsani A Nat Aging. 2025; .

PMID: 40044970 DOI: 10.1038/s43587-025-00819-z.


Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations.

Ji X, Jiang R, Liu T, Provencio M, Lee S, Zhan Q Transl Lung Cancer Res. 2024; 13(7):1695-1707.

PMID: 39118876 PMC: 11304138. DOI: 10.21037/tlcr-24-477.


Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.

Wauters A, Scheerstra J, van Leent M, Teunissen A, Priem B, Beldman T Nat Nanotechnol. 2024; 19(11):1735-1744.

PMID: 39085390 PMC: 11567884. DOI: 10.1038/s41565-024-01727-w.


A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors.

Fenniche S, Oukabli M, Oubaddou Y, Chahdi H, Damiri A, Alghuzlan A Curr Issues Mol Biol. 2023; 45(7):5811-5823.

PMID: 37504283 PMC: 10378117. DOI: 10.3390/cimb45070367.


References
1.
Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

2.
Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

3.
Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View

4.
Sabra M, Dominguez J, Grewal R, Larson S, Ghossein R, Tuttle R . Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013; 98(5):E829-36. PMC: 3644606. DOI: 10.1210/jc.2012-3933. View

5.
Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E . Harnessing innate immunity in cancer therapy. Nature. 2019; 574(7776):45-56. DOI: 10.1038/s41586-019-1593-5. View